Exelixis, Inc. (EXEL)

Market Cap	10.31B
Revenue (ttm)	2.17B
Net Income (ttm)	521.27M
Shares Out	279.88M
EPS (ttm)	1.76
PE Ratio	20.94
Forward PE	18.18
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,409,359
Open	36.00
Previous Close	35.09
Day's Range	35.88 - 37.05
52-Week Range	20.14 - 37.59
Beta	0.53
Analysts	Buy
Price Target	37.24 (+1.06%)
Earnings Date	Feb 11, 2025

About EXEL

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF recep...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Apr 7, 2000
• Employees: 1,147
• Stock Exchange: NASDAQ
• Ticker Symbol: EXEL
• Website: https://www.exelixis.com

Financial Performance

In 2024, Exelixis's revenue was $2.17 billion, an increase of 18.49% compared to the previous year's $1.83 billion. Earnings were $521.27 million, an increase of 150.89%.

Analyst Forecast

According to 18 analysts, the average rating for EXEL stock is "Buy." The 12-month stock price forecast is $37.24, which is an increase of 1.06% from the latest price.

Price Target

$37.24

(1.06% upside)

Analyst Consensus: Buy